124 related articles for article (PubMed ID: 35594440)
1. Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator.
Nakano T; Tagashira Y; Egashira S; Morimoto M; Irie K; Hosokawa M; Hayashi T; Egawa T; Hayakawa K; Mishima K
Neuroreport; 2022 May; 33(7):297-303. PubMed ID: 35594440
[TBL] [Abstract][Full Text] [Related]
2. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Nakano T; Irie K; Hayakawa K; Sano K; Nakamura Y; Tanaka M; Yamashita Y; Satho T; Fujioka M; Muroi C; Matsuo K; Ishikura H; Futagami K; Mishima K
Brain Res; 2015 Oct; 1624():330-335. PubMed ID: 26254727
[TBL] [Abstract][Full Text] [Related]
3. Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
Li M; Chen S; Shi X; Lyu C; Zhang Y; Tan M; Wang C; Zang N; Liu X; Hu Y; Shen J; Zhou L; Gu Y
J Neuroinflammation; 2018 Aug; 15(1):237. PubMed ID: 30139371
[TBL] [Abstract][Full Text] [Related]
4. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
Wang Y; Zhang Z; Chow N; Davis TP; Griffin JH; Chopp M; Zlokovic BV
Stroke; 2012 Sep; 43(9):2444-9. PubMed ID: 22811462
[TBL] [Abstract][Full Text] [Related]
5. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Liu W; Hendren J; Qin XJ; Liu KJ
Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
[TBL] [Abstract][Full Text] [Related]
6. Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
Liu DL; Hong Z; Li JY; Yang YX; Chen C; Du JR
J Neuroinflammation; 2021 Jun; 18(1):143. PubMed ID: 34162400
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting 12/15-lipoxygenase to treat acute stroke in permanent and tPA induced thrombolysis models.
Karatas H; Eun Jung J; Lo EH; van Leyen K
Brain Res; 2018 Jan; 1678():123-128. PubMed ID: 29079502
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Li Y; Zhu ZY; Lu BW; Huang TT; Zhang YM; Zhou NY; Xuan W; Chen ZA; Wen DX; Yu WF; Li PY
CNS Neurosci Ther; 2019 Dec; 25(12):1343-1352. PubMed ID: 31756041
[TBL] [Abstract][Full Text] [Related]
9. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
[TBL] [Abstract][Full Text] [Related]
10. Prothymosin alpha and its mimetic hexapeptide improve delayed tissue plasminogen activator-induced brain damage following cerebral ischemia.
Halder SK; Matsunaga H; Ueda H
J Neurochem; 2020 Jun; 153(6):772-789. PubMed ID: 31454420
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Liu H; Wang Y; Xiao Y; Hua Z; Cheng J; Jia J
Transl Stroke Res; 2016 Jun; 7(3):209-19. PubMed ID: 27018013
[TBL] [Abstract][Full Text] [Related]
12. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
[TBL] [Abstract][Full Text] [Related]
13. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke.
Yu S; Liu X; Shen Y; Xu H; Yang Y; Ding F
Neuroscience; 2016 Jul; 327():44-52. PubMed ID: 27060484
[TBL] [Abstract][Full Text] [Related]
15. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Shimada Y; Shimura H; Tanaka R; Yamashiro K; Koike M; Uchiyama Y; Urabe T; Hattori N
PLoS One; 2018; 13(5):e0198039. PubMed ID: 29795667
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic tPA-induced hemorrhagic transformation of ischemic stroke is mediated by PKCβ phosphorylation of occludin.
Goncalves A; Su EJ; Muthusamy A; Zeitelhofer M; Torrente D; Nilsson I; Protzmann J; Fredriksson L; Eriksson U; Antonetti DA; Lawrence DA
Blood; 2022 Jul; 140(4):388-400. PubMed ID: 35576527
[TBL] [Abstract][Full Text] [Related]
18. GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats.
Wang W; Li M; Wang Y; Li Q; Deng G; Wan J; Yang Q; Chen Q; Wang J
Mol Neurobiol; 2016 Dec; 53(10):7028-7036. PubMed ID: 26671619
[TBL] [Abstract][Full Text] [Related]
19. Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.
Gautier S; Ouk T; Tagzirt M; Lefebvre C; Laprais M; Pétrault O; Dupont A; Leys D; Bordet R
J Neuroinflammation; 2014 May; 11():96. PubMed ID: 24885160
[TBL] [Abstract][Full Text] [Related]
20. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.
García-Yébenes I; Sobrado M; Zarruk JG; Castellanos M; Pérez de la Ossa N; Dávalos A; Serena J; Lizasoain I; Moro MA
Stroke; 2011 Jan; 42(1):196-203. PubMed ID: 21106952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
